Evvy has successfully raised $40 million in a Series B funding round to scale its precision medicine platform focused on women's health. The newly signed round was led by Catalio Capital Management. Other investors participating in the financing included Rethink Impact, Muse Capital, Alumni Ventures, Labcorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, and others.
With this new capital, Evvy's total funding has reached nearly $60 million. The company was founded in New York in 2021. Evvy's co-founders are Priyanka Jain, who serves as CEO, along with Line Bruezek and Pita Navarro. Initially, the company focused on testing vaginal microbiome.
The Evvy platform uses metagenomic sequencing to analyze over 700 microbes from a single sample. Users collect samples at home and then send them to the Evvy laboratory. Clinicians then analyze the results through the company's platform, providing patients with clinical conclusions and personalized treatment plans. The system also supports tracking long-term biomarkers.
According to Evvy, its platform currently serves over 100,000 patients across the United States and collaborates with more than 3,000 practicing physicians. The company has accumulated an extensive dataset that has allowed it to publish peer-reviewed studies and identify previously uncatalogued vaginal microbiome genomes, as well as new subtypes of bacterial vaginosis. This data can help doctors develop more personalized treatment methods.
Evvy's broader goals extend beyond just vaginal health; the company aims to link microbiome biology with symptoms, treatments, and health outcomes. The company believes that high-quality data on women's health remains limited, creating obstacles for the development of artificial intelligence and precision medicine. Evvy intends to bridge this gap by collecting large volumes of biological data, which could potentially help researchers uncover links between molecular signals and health status.
In May, the company launched EvvyAI—an AI-powered assistant that translates microbiome data into personalized recommendations for users. This system combines automated insights with clinician oversight, allowing patients to be referred to doctors when professional medical judgment is necessary.
The new funding will be directed towards expanding Evvy's work in fertility. The company is investigating the relationship between the vaginal microbiome and reproductive outcomes, including infertility, IVF success rates, and recurrent pregnancy loss. Furthermore, research is underway on potential links to preterm birth and gynecological cancer. Last year, Evvy launched a prospective study in collaboration with IVF clinics, using vaginal microbiome testing to gather additional clinical data.
Evvy plans to use the new capital to validate AI-based diagnostic and treatment models. Fertility will be the first major area of expansion outside of vaginal health. The company will also increase service reach through partner and physician channels, deepening its collaboration with US Fertility. In the long term, the Evvy platform could cover a wider range of women's health conditions, offering an alternative to traditional screening methods through regular at-home testing. Potential areas include inflammation, infections, endometriosis, and fertility.
Catalio Capital Management noted that Evvy's data and AI infrastructure is a key factor in their investment, while also highlighting the company's growth and the quality of its leadership team. Evvy enters the women's health market, which is attracting growing investor attention, and the new funding provides the company with additional resources to expand diagnostic coverage, combining clinical testing, proprietary biological data, and artificial intelligence.



